Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation

Fusion Antibodies secures USD460,000 in follow-on contracts with US biotechnology client

INOVIO to begin rolling submission of BLA for INO-3107

ZYUS Life Sciences begins Phase 2a cancer pain trial with first patient enrolled

Curasight secures approval for phase 1 trial of uTREAT in glioblastoma patients

Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension

Calluna Pharma begins Phase 2 study of CAL101 in idiopathic pulmonary fibrosis

European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo

BioArctic and Novartis sign an option, collaboration and license agreement

Curasight's uTREAT clinical trial application approved in Europe

Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial

Lighthouse Pharmaceuticals announces receipt of USD49.2m grant from NIA for LHP588 study

Innovent Biologics receives approval over squamous cell lung cancer study

Cambrex announces expansion of peptide manufacturing capabilities in Waltham, Massachusetts

Tyra Biosciences doses first child in dabogratinib Phase 2 achondroplasia clinical study